Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings
31 August 2023 - 6:01AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it will present new and encore data at the 35th International
Epilepsy Congress (IEC) and the American College of Clinical
Pharmacology (ACCP) Annual Meeting.
Presentation Details:
IEC September 2-6, 2023 – Dublin, Ireland
- Title: A Phase 1 Clinical Study Shows Robust LP352 CSF
Exposures Supporting Dose Optimization for 5-HT2C Receptor
Engagement (#746) Details: Digital poster
- Title: The PACIFIC Study: A Phase 1b/2a Study to
Investigate the Safety, Tolerability, Pharmacology, and Exploratory
Efficacy of LP352 in Subjects With Developmental and Epileptic
Encephalopathies (#758) Oral Presentation Date/Time:
September 5, 2:00 PM-2:30 PM GMT
- Title: Searching for Safer and More Effective
Medications in the Management of Seizure Disorders: A 5-HT2C
Superagonist (#754) Oral Presentation Date/Time: September
5, 2:00 PM-2:30 PM GMT
- Title: Evaluation of Prolactin as a Useful
Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C
Receptors by LP352, a Potent and Selective 5-HT2C Agonist (#749)
Oral Presentation Date/Time: September 5, 2:00 PM-2:30 PM
GMT All posters will be available digitally throughout the duration
of the conference
ACCP September 10-12, 2023 – Bellevue, WA
- Title: A Phase 1 Study of 5-HT2C Superagonist LP352
Shows Robust Brain Penetration, a Strong Correlation Between Plasma
and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor
Engagement (#060) Oral Presentation Date/Time: September 10,
5:00 PM-7:00 PM PT
ABOUT LP352
LP352 is an oral, centrally acting, 5-HT2C superagonist in
development for the potential treatment of seizures associated with
DEEs such as Lennox-Gastaut syndrome, Dravet syndrome,
SCN2A-related epilepsies, CDKL5 deficiency disorder, and other
epileptic disorders. LP352 is designed to modulate GABA and, as a
result, suppress the central hyperexcitability that is
characteristic of seizures. LP352 has no detected activity at the
5-HT2B and 5-HT2A receptor subtypes. 5-HT2B and 5-HT2A receptor
agonism have been associated with significant adverse side effects.
LP352 has novel chemistry and attributes. It was designed to be
more specific and selective for the 5-HT2C receptor subtype, giving
it the potential to reduce seizures in patients with DEEs while
overcoming the known or perceived safety limitations of available
drugs in the 5-HT2 class. LP352 is currently being evaluated in a
Ph 1b/2a clinical trial (the PACIFIC Study) in participants with
DEEs, with data expected around year-end 2023, as well as in
additional supportive studies.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
detectable activity on 5-HT2B and 5-HT2A receptor subtypes, in
development for the potential treatment of seizures associated with
a broad range of Developmental and Epileptic Encephalopathies.
Longboard is also evaluating LP659, an oral, centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
which is in development for the potential treatment of multiple
neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in the upcoming meetings and Longboard’s clinical and
preclinical programs and product candidates, ability to develop
product candidates and deliver medicines, and focus. For such
statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230830992609/en/
CORPORATE CONTACT: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024